Academic Journal
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
| العنوان: | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) |
|---|---|
| المؤلفون: | Andrew G. Sikora, Kevin J. Harrington, R. Bryan Bell, Maura L. Gillison, Quynh-Thu Le, Nancy Y. Lee, Rebecca L. Lewis, Loren K. Mell, Adam Raben, Ravindra Uppaluri, Fernanda Whitworth, Dan P. Zandberg |
| المصدر: | Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019) |
| بيانات النشر: | BMJ Publishing Group |
| سنة النشر: | 2019 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing. These consensus guidelines serve as a ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2051-1426 |
| Relation: | https://jitc.bmj.com/content/7/1/184.full; https://doaj.org/toc/2051-1426; https://doaj.org/article/ec9804eba34044ffba07cada41e82843 |
| DOI: | 10.1186/s40425-019-0662-5 |
| الاتاحة: | https://doi.org/10.1186/s40425-019-0662-5 https://doaj.org/article/ec9804eba34044ffba07cada41e82843 |
| رقم الانضمام: | edsbas.307DB1AD |
| قاعدة البيانات: | BASE |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.307DB1AD 893 3 Academic Journal academicJournal 892.664306640625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.307DB1AD&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1186/s40425-019-0662-5# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsbas&genre=article&issn=20511426&ISBN=&volume=&issue=&date=20190101&spage=&pages=&title=Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019&atitle=The%20Society%20for%20Immunotherapy%20of%20Cancer%20consensus%20statement%20on%20immunotherapy%20for%20the%20treatment%20of%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20%28HNSCC%29&id=DOI:10.1186/s40425-019-0662-5 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Andrew+G%2E+Sikora%22">Andrew G. Sikora</searchLink><br /><searchLink fieldCode="AR" term="%22Kevin+J%2E+Harrington%22">Kevin J. Harrington</searchLink><br /><searchLink fieldCode="AR" term="%22R%2E+Bryan+Bell%22">R. Bryan Bell</searchLink><br /><searchLink fieldCode="AR" term="%22Maura+L%2E+Gillison%22">Maura L. Gillison</searchLink><br /><searchLink fieldCode="AR" term="%22Quynh-Thu+Le%22">Quynh-Thu Le</searchLink><br /><searchLink fieldCode="AR" term="%22Nancy+Y%2E+Lee%22">Nancy Y. Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Rebecca+L%2E+Lewis%22">Rebecca L. Lewis</searchLink><br /><searchLink fieldCode="AR" term="%22Loren+K%2E+Mell%22">Loren K. Mell</searchLink><br /><searchLink fieldCode="AR" term="%22Adam+Raben%22">Adam Raben</searchLink><br /><searchLink fieldCode="AR" term="%22Ravindra+Uppaluri%22">Ravindra Uppaluri</searchLink><br /><searchLink fieldCode="AR" term="%22Fernanda+Whitworth%22">Fernanda Whitworth</searchLink><br /><searchLink fieldCode="AR" term="%22Dan+P%2E+Zandberg%22">Dan P. Zandberg</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => BMJ Publishing Group ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Directory of Open Access Journals: DOAJ Articles ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing. These consensus guidelines serve as a ... ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2051-1426 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://jitc.bmj.com/content/7/1/184.full; https://doaj.org/toc/2051-1426; https://doaj.org/article/ec9804eba34044ffba07cada41e82843 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1186/s40425-019-0662-5 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1186/s40425-019-0662-5<br />https://doaj.org/article/ec9804eba34044ffba07cada41e82843 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.307DB1AD ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1186/s40425-019-0662-5
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens
[Type] => general
)
[1] => Array
(
[SubjectFull] => RC254-282
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Andrew G. Sikora
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kevin J. Harrington
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => R. Bryan Bell
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Maura L. Gillison
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Quynh-Thu Le
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nancy Y. Lee
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rebecca L. Lewis
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Loren K. Mell
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Adam Raben
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ravindra Uppaluri
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fernanda Whitworth
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dan P. Zandberg
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 20511426
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1 (2019
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |